Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
80.7M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
35.3M
-
Shares change
-
-7.67M
-
Total reported value, excl. options
-
$125M
-
Value change
-
-$30M
-
Put/Call ratio
-
0.46
-
Number of buys
-
68
-
Number of sells
-
-69
-
Price
-
$3.53
Significant Holders of Altimmune, Inc. - Common Stock (ALT) as of Q2 2023
184 filings reported holding ALT - Altimmune, Inc. - Common Stock as of Q2 2023.
Altimmune, Inc. - Common Stock (ALT) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.3M shares
of 80.7M outstanding shares and own 43.7% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.66M shares), Nuveen Asset Management, LLC (3.46M shares), VANGUARD GROUP INC (3.31M shares), TANG CAPITAL MANAGEMENT LLC (2.75M shares), MARSHALL WACE, LLP (2.06M shares), Laurion Capital Management LP (1.84M shares), Avidity Partners Management LP (1.17M shares), MORGAN STANLEY (1.08M shares), ARDSLEY ADVISORY PARTNERS LP (1.04M shares), and TWO SIGMA INVESTMENTS, LP (987K shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.